Novo Nordisk Shares Soar 7.77% on Strong Q1 Earnings

On May 7, 2025, Novo Nordisk's stock surged by 7.77% in pre-market trading, reflecting strong investor confidence in the company's recent performance and future prospects.

Novo Nordisk reported robust financial results for the first quarter of 2025, with global sales reaching 780.87 billion Danish kroner, an 18% increase compared to the same period last year. The company's diabetes and obesity treatment products continued to drive revenue growth, with GLP-1 based treatments such as Ozempic, Rybelsus, and Wegovy contributing significantly to the top line.

In China, Novo Nordisk achieved remarkable growth, with revenues increasing by 25% year-over-year to 56.22 billion Danish kroner. This growth was largely driven by the strong performance of the company's GLP-1 based products, which have been well-received in the Chinese market.

Novo Nordisk also made significant progress in its research and development efforts. The company announced that its CagriSema combination therapy achieved a 15.7% average weight loss in patients with obesity or overweight and type 2 diabetes in the REDEFINE 2 Phase III clinical trial. Additionally, Novo Nordisk submitted regulatory applications for semaglutide 2.4 mg for the treatment of MASH, which has been granted priority review status by the FDA.